LOL—It’s about perceived potential and de-risked pathways. Wall Street invests when it sees a credible shot at success, often before profitability. NWBO's DCVax offers a derisked investment with unlimited upside due to its proven, peer-reviewed efficacy, potential of becoming SOC, infinite scalability, and patent protection.
So, let’s simplify my thesis: if DCVax-L secures MHRA approval and lands multiple Big Pharma partnerships, that’s dual validation—regulatory and peer-based. At that point, Wall Street isn’t waiting for massive revenue. It’s reacting to minimized risk and increased credibility. This is a risk-adjusted entry thesis. And in biotech, that’s often the inflection point. Put it to rest, Smitty.
You keep circling back to the current share price and the time it has taken to reach this point. Additionally, you keep bringing up other topics (PPS predictions of $10-$30) that I haven't even mentioned. These issues may make you feel better emotionally, but they are irrelevant to the core point:
MHRA approval + multiple BP partnerships = minimized risk = significant investment into NWBO BEFORE massive revenues are in the picture. Is it your position that if DCVax received MHRA approval and NWBO entered into multiple BP partnerships, Wall Street would not invest in NWBO, Yes or NO?
Market Data 
Markets 
AI
